Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant MelanomaKelsey W. Nassar, Rebecca E. Schweppe|Molecular Cancer Therapeutics|2021Cited by 37